Menu
Menu
Develop and make broadly available a robust, economically viable, shared-access platform for the technical development, manufacturing, and characterization of AAV-based gene therapy vectors. Ensure that workforce training for this platform can integrate into existing curriculum or training models to encourage adoption, and integrate improvements into the platform based on feedback from these training programs.
A gene-based therapeutics industry capable of serving patients across the full spectrum of unmet needs—from prevalent indications to ultra-rare diseases—that has access to high-quality viral vectors without cost or speed limitations.
One of the most important vector platforms in use in the biopharmaceutical industry today is adeno-associated virus (AAV) vectors. Our Program focuses on advancing the manufacturing process and analytical capabilities for AAV vectors. The advances are critical for broad and rapid expansion of the emerging industry of gene-based therapeutics and ultimately the many patients and families who can benefit from access to these novel therapies.
NIIMBL is well-positioned to bring together the right resources to accelerate development of core manufacturing process platforms and essential analytical capabilities for viral vector product and process characterization, which can
The work of the program is organized around workstreams, topical focus areas.
Objective: Develop broadly available, robust, replicable, well-understood, and documented AAV manufacturing process.
Objective: Drive and demonstrate process capabilities enabling broad expansion of AAV gene therapy applications
Objective: Develop and disseminate AAV analytical capabilities for process and product characterization, batch release, and stability monitoring
Objective: Support availability and utilization of physical and documentary standards, reference materials, and data.
Alliance for Regenerative Medicine
AstraZeneca
Batavia Biosciences Inc
Bristol-Myers Squibb
Cytiva
Eli Lilly and Company
Federal Stakeholder: National Institute of Standards and Technology
Federal Stakeholder: Food and Drug Administration
Genentech
Joan & Sanford I. Weill Medical College of Cornell University
Landmark Bio
Lonza Biologics, Inc.
MilliporeSigma/EMD Serono
NIIMBL
North Carolina State University
Pfizer, Inc.
Sartorius Stedim
Spark Therapeutics, Inc.
United States Pharmacopeial Convention
University of Florida
University of Massachusetts Medical School
University of Massachusetts System
Virica Biotech Inc.
The program focuses on five key areas — standardization and contextualization, end-to-end automated control of critical quality attributes (CQAs), multivariate sensors and analytics, advanced control strategies, and bioprocess modeling and simulation – that will enable biomanufacturers to harness the power of data for real-time decision-making.
This program brings together stakeholders and resources to collaboratively identify opportunities to advance manufacturing related issues relevant to the development and distribution of vaccines.
The NIIMBL community is collaborating on an integrated approach to create flexibility, improve control and security of the supply chain, foster sustainability, and reduce costs in biopharmaceutical manufacturing.
To access more program information, including:
Learn more about how being a member of NIIMBL can grant you and your company access to NIIMBL-led programs and other collaboration opportunities.
